E B Keeffe

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Retreatment of chronic hepatitis C virus infection
    Joseph K Lim
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Rev Gastroenterol Disord 4:97-103. 2004
  2. ncbi Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection
    Seth D Crockett
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Ann Clin Microbiol Antimicrob 4:13. 2005
  3. ncbi Current treatment strategies for chronic hepatitis B and C
    O S Lin
    Division of Gastroenterology, Department of Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    Annu Rev Med 52:29-49. 2001
  4. ncbi Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Semin Liver Dis 23:1-2. 2003
  5. ncbi [Acute liver failure]
    Emmet B Keeffe
    División de Gastroenterología y Hepatología, Departmento de Medicina, Stanford University School of Medicine, Stanford, CA, USA
    Rev Gastroenterol Mex 70:56-62. 2005
  6. ncbi A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 6:1315-41; quiz 1286. 2008
  7. ncbi Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Trans Am Clin Climatol Assoc 117:227-37; discussion 237-8. 2006
  8. ncbi A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, CA 94304, USA
    Clin Gastroenterol Hepatol 4:936-62. 2006
  9. ncbi Chronic hepatitis B: preventing, detecting, and managing viral resistance
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Gastroenterol Hepatol 6:268-74. 2008
  10. ncbi Future treatment of chronic hepatitis C
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Antivir Ther 12:1015-25. 2007

Detail Information

Publications105 found, 100 shown here

  1. ncbi Retreatment of chronic hepatitis C virus infection
    Joseph K Lim
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Rev Gastroenterol Disord 4:97-103. 2004
    ..The growing number of patients who have been treated and have failed initial therapy highlights the need for the development of more efficacious antiviral agents for the treatment of chronic hepatitis C...
  2. ncbi Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection
    Seth D Crockett
    Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Ann Clin Microbiol Antimicrob 4:13. 2005
    ..The natural history and treatment of patients with HBV and HCV coinfection is reviewed...
  3. ncbi Current treatment strategies for chronic hepatitis B and C
    O S Lin
    Division of Gastroenterology, Department of Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    Annu Rev Med 52:29-49. 2001
    ..Interferon combined with polyethylene glycol (PEG), shows promise as an improved formulation of interferon with yet higher sustained response rates...
  4. ncbi Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Semin Liver Dis 23:1-2. 2003
  5. ncbi [Acute liver failure]
    Emmet B Keeffe
    División de Gastroenterología y Hepatología, Departmento de Medicina, Stanford University School of Medicine, Stanford, CA, USA
    Rev Gastroenterol Mex 70:56-62. 2005
    ..The focus of management of acute liver failure is comprehensive supportive care in an intensive care unit and assessment of the need for liver transplantation...
  6. ncbi A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 6:1315-41; quiz 1286. 2008
    ..Issues for consideration for therapy include efficacy, safety, rate of resistance, method of administration, and cost...
  7. ncbi Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Trans Am Clin Climatol Assoc 117:227-37; discussion 237-8. 2006
    ..Vaccination rates are low in clinical practice, and public health and educational programs are needed to overcome barriers to facilitate timely implementation of these recommendations...
  8. ncbi A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, CA 94304, USA
    Clin Gastroenterol Hepatol 4:936-62. 2006
    ..Issues for consideration include efficacy, safety, incidence of resistance, method of administration, and cost...
  9. ncbi Chronic hepatitis B: preventing, detecting, and managing viral resistance
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Gastroenterol Hepatol 6:268-74. 2008
    ..Despite the substantial advances in treatment made to date, new agents with novel viral targets will be needed for patients who ultimately may fail second- or third-line therapy...
  10. ncbi Future treatment of chronic hepatitis C
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Antivir Ther 12:1015-25. 2007
    ....
  11. ncbi Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
    Emmet B Keeffe
    Stanford University School of Medicine, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 5:890-7. 2007
    ..Future studies of the use of the roadmap concept in improving outcomes of chronic hepatitis B are warranted...
  12. ncbi Chronic hepatitis C: management of treatment failures
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304 1509, USA
    Clin Gastroenterol Hepatol 3:S102-5. 2005
    ....
  13. ncbi Update on liver transplantation
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Rev Gastroenterol Mex 69:160-70. 2004
  14. ncbi New and emerging treatment of chronic hepatitis B
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA
    Clin Gastroenterol Hepatol 5:285-94. 2007
    ..This review summarizes the recent clinical studies of these new agents and discusses the implications of these data for the management of chronic hepatitis B...
  15. ncbi A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
    Emmet B Keeffe
    Stanford University Medical Center, 750 Welch Road, Suite 210, Palo Alto, California 94304 1509, USA
    Clin Gastroenterol Hepatol 2:87-106. 2004
    ....
  16. ncbi Liver transplantation at the millennium. Past, present, and future
    E B Keeffe
    Division of Gastroenterology, Department of Medicine, Stanford University School of Medicine, California, USA
    Clin Liver Dis 4:241-55. 2000
    ..Liver transplantation has come a long way from the initial, unsuccessful human transplantations in 1963, but many challenges remain...
  17. ncbi Liver transplantation: current status and novel approaches to liver replacement
    E B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine and Liver Transplant Program, Stanford University Medical Center, Stanford, California 94304 1509, USA
    Gastroenterology 120:749-62. 2001
    ....
  18. ncbi Occupational risk for hepatitis A: a literature-based analysis
    Emmet B Keeffe
    Stanford University School of Medicine, Stanford, CA, USA
    J Clin Gastroenterol 38:440-8. 2004
    ..Additionally, food handlers, particularly in the hospital setting, should be vaccinated if seronegative for hepatitis A virus because of their ability to rapidly spread disease among vulnerable populations if infected...
  19. ncbi Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group
    E B Keeffe
    Stanford University Medical Center, Palo Alto, CA 94304 1509, USA
    Cytokines Cell Mol Ther 5:207-10. 1999
    ..Similar results were obtained based on HCV antibody typing and genotyping, suggesting the potential of the former for predicting response to interferon...
  20. ncbi Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group
    E B Keeffe
    Stanford University Medical Center, Palo Alto, CA 94304 1509, USA
    Cytokines Cell Mol Ther 5:211-6. 1999
    ..In summary, both genotype and ultimate response to treatment are determinants of the pattern and rate of serum HCV RNA change during interferon therapy of chronic hepatitis C...
  21. ncbi Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?
    S K So
    Department of Surgery and Medicine, Stanford Asia Liver Center, Stanford University School of Medicine, California, USA
    J Gastroenterol Hepatol 14:S48-52. 1999
    ..The incidence of post-transplant HBV recurrence was similar: 0% in Asians compared with 7% in non-Asians. There was no recurrence in the group of 12 patients who were HBV-DNA or HBeAg negative pretransplant...
  22. ncbi Review article: current antiviral therapy of chronic hepatitis B
    W S Ayoub
    Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA
    Aliment Pharmacol Ther 28:167-77. 2008
    ..The long-term goals of therapy for chronic hepatitis B are to reduce serum HBV DNA to low or undetectable levels and ultimately reduce or prevent the development of cirrhosis and hepatocellular carcinoma...
  23. ncbi Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides
    M H Nguyen
    Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA 94304, USA
    J Viral Hepat 16:149-55. 2009
    ....
  24. ncbi Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Rev Gastroenterol Disord 4:S14-21. 2004
    ..The limited data on antiviral therapy in patients with genotypes 4 to 9 highlight the need for further and controlled treatment trials in these populations...
  25. ncbi Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation
    W De Luna
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Am J Transplant 9:1158-68. 2009
    ....
  26. ncbi Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B
    Natalie Bzowej
    California Pacific Medical Center, San Francisco, CA, USA
    Liver Transpl 15:1010-20. 2009
    ..Our finding of a higher rate of HBV recurrence among Caucasians needs to be validated in other studies...
  27. ncbi Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C
    Philip Vutien
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA
    Am J Gastroenterol 105:1110-5. 2010
    ..Our goal was to compare SVR rates among Caucasian and Asian-American patients with genotype 1 and 2/3 infection whose HCV genotypes were accurately classified by core sequencing testing...
  28. ncbi Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA
    Am J Gastroenterol 103:1131-5. 2008
    ..No study to date has examined the treatment response to peginterferon and ribavirin (PEG IFN + RBV) in these patients, or the effects of treatment duration on sustained virologic response (SVR) rates...
  29. ncbi Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period
    Andy S Yu
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
    Clin Liver Dis 7:551-72. 2003
    ..Other therapeutic alternatives in the future may include gene therapy and immune interventions...
  30. ncbi Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C
    A Zaman
    Division of Gastroenterology and Hepatology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Aliment Pharmacol Ther 18:661-70. 2003
    ..Randomized controlled trials over the last decade have demonstrated incremental improvement in the treatment efficacy of chronic hepatitis C with combination interferon and ribavirin therapy when compared with interferon monotherapy...
  31. ncbi Hepatitis C virus and liver transplantation
    A Ahmed
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Liver Transplant Program, Stanford University Medical Center, Stanford, California, USA
    Clin Liver Dis 5:1073-90. 2001
    ....
  32. ncbi Chronic hepatitis B and hepatitis C in Asian Americans
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Rev Gastroenterol Disord 3:125-34. 2003
    ..S. population. This review briefly summarizes the major issues in the clinical care of patients with chronic viral hepatitis and focuses on pertinent epidemiological and clinical differences between Asian-American and Caucasian patients...
  33. ncbi Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy
    Gaurav Arora
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Rev Gastroenterol Disord 7:63-73. 2007
    ..This article focuses on 3 of these drugs--lamivudine, adefovir, and entecavir--and their use in patients with chronic HBV infection and advanced hepatic fibrosis or cirrhosis...
  34. ncbi Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients
    E Y Ho
    Department of Medicine, Stanford University Medical Center, Palo Alto, CA 94304, USA
    J Viral Hepat 19:e105-11. 2012
    ..These findings may guide the development of HCV screening in our increasingly diverse population...
  35. ncbi Liver transplantation: evolving patient selection criteria
    A S Yu
    Department of Medicine, Stanford University Medical Center, Stanford, CA 94304-1509, USA
    Can J Gastroenterol 15:729-38. 2001
    ....
  36. ncbi Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
    Scott K Fung
    Division of Gastroenterology, University of Michigan, Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA
    J Hepatol 43:937-43. 2005
    ..CONCLUSIONS: In conclusion, adefovir resistance can be associated with significant viral rebound and hepatic decompensation which may be fatal...
  37. ncbi Update on chronic hepatitis C
    Aijaz Ahmed
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    Compr Ther 29:224-32. 2003
    ..Liver biopsy is now used selectively rather than routinely, and the combination peginterferon plus ribavirin is the treatment of choice for the majority of patients...
  38. ncbi Patient selection and listing policies for liver transplantation
    E B Keeffe
    Department of Medicine, Stanford University School of Medicine, California, USA
    J Gastroenterol Hepatol 14:S42-7. 1999
    ..Finally, cost-outcome analyses and the reality of managed care with the transfer of financial risk from insurers to providers is beginning to have an influence on patient selection criteria...
  39. ncbi Hematologic side effects of PEG interferon and ribavirin. Management with growth factors
    Emmet B Keeffe
    Stanford University Medical Center, Palo Alto, CA
    J Clin Gastroenterol 39:S1-2. 2005
  40. ncbi Review article: current antiviral therapy of chronic hepatitis B
    W S Ayoub
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, 750 Welch Road, Stanford, CA 94304, USA
    Aliment Pharmacol Ther 34:1145-58. 2011
    ..The aim of the therapy for chronic hepatitis B is to achieve a long-term continued suppression of the hepatitis B virus (HBV) DNA to prevent disease progression leading to the development of cirrhosis and hepatocellular carcinoma...
  41. ncbi Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance
    D Bhattacharya
    Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
    Int J STD AIDS 19:780-1. 2008
    ..In HIV/HBV co-infection, measurement of HBV DNA and HBV resistance mutations may identify HBV virological failure before biochemical changes and should be routinely used in the management of HIV/HBV co-infection...
  42. ncbi Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver
    J Boisvert
    Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA
    J Infect Dis 184:827-35. 2001
    ..No HCV replicating in peripheral leukocytes was detected by a highly sensitive assay. If HCV replication occurs in the leukocyte subsets analyzed here, it is at extremely low levels or occurs under alternate physiological conditions...
  43. ncbi Hepatitis B vaccines
    Andy S Yu
    Liver Transplant Program, Stanford University Medical Center, 750 Welch Road, Suite 210, Stanford, CA 94305, USA
    Clin Liver Dis 8:283-300. 2004
    ..For those who remain nonresponders after the second series of vaccination, adjuvants such as GM-CSF may be considered, but their results are variable...
  44. ncbi Chronic hepatitis C with normal aminotransferase levels
    Aijaz Ahmed
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Gastroenterology 126:1409-15. 2004
  45. ncbi Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
    J F Rossignol
    The Romark Institute for Medical Research, Tampa, FL, and Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Aliment Pharmacol Ther 28:574-80. 2008
    ..Nitazoxanide, licensed in the US for treatment of Cryptosporidium parvum and Giardia lamblia, inhibits hepatitis C virus replication in replicon systems...
  46. ncbi Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection
    H E Kohrt
    Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA
    Aliment Pharmacol Ther 24:1003-16. 2006
    ..It is thus recommended that all hepatitis B surface antigen carriers receive lamivudine, or a comparable anti-viral agent, as prophylaxis from the initiation of chemotherapy until at least 1 year following its completion...
  47. ncbi Resection versus transplantation for hepatocellular carcinoma
    C O Esquivel
    Department of Surgery, Stanford University School of Medicine, California, USA
    J Gastroenterol Hepatol 14:S37-41. 1999
    ..This review will address the results observed following resection or transplantation for hepatocellular carcinoma...
  48. ncbi Endoscopic gastrointestinal manifestations of liver disease
    R C Cheung
    Division of Gastroenterology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Gastrointest Endosc Clin N Am 11:15-44. 2001
    ..In the lower gastrointestinal tract, portal hypertension may be associated with hemorrhoids, anorectal varices, and portal hypertensive colopathy, all of which are occasional causes of gastrointestinal bleeding...
  49. ncbi Review article: hepatitis vaccination in patients with chronic liver disease
    G Reiss
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Aliment Pharmacol Ther 19:715-27. 2004
    ..Hepatitis A and B vaccination should be part of the routine management of patients with chronic liver disease, preferably as early as possible in the natural course of their disease...
  50. ncbi Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: a systematic review
    D M Bravata
    Department of Veterans Affairs Health Care System, Palo Alto, CA, USA
    Liver Transpl 7:191-203. 2001
    ..The proportions of transplant recipients with ALD and non-ALD reporting alcohol use did not differ, although those with ALD tended to consume greater quantities...
  51. ncbi Role of liver biopsy in the management of chronic liver disease: selective rather than routine
    Gary Reiss
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Rev Gastroenterol Disord 5:195-205. 2005
    ....
  52. ncbi Chronic hepatitis C: genotypes 4 to 9
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Clin Liver Dis 9:411-26, vi. 2005
    ..This article reviews the existing literature, which suggests that chronic hepatitis C with genotypes 4 through 9 may exhibit epidemiologic, clinical, and treatment outcome differences from infection with genotypes 1, 2, or 3...
  53. ncbi Viral hepatitis and other infectious diseases in a homeless population
    Ramsey C Cheung
    Division of Gastroenterology and Hepatology, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Clin Gastroenterol 34:476-80. 2002
    ..To determine the prevalence of four common infectious diseases-hepatitis B, hepatitis C, human immunodeficiency virus (HIV), and tuberculosis-as well as co-infection rates and risk factors in a homeless population...
  54. ncbi Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA 94304 1509, USA
    Clin Gastroenterol Hepatol 3:S97-S101. 2005
    ..The optimal duration of treatment (24 vs 48 wk) for HCV genotype 6 is unclear and currently is under investigation...
  55. ncbi Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Am J Med 118:21S-27S. 2005
    ....
  56. ncbi Prevalence of HBV precore/core promoter variants in the United States
    Chi-Jen Chu
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
    Hepatology 38:619-28. 2003
    ..Physicians should be aware of the existence of HBV precore and core promoter variants and the clinical condition of "HBeAg-negative chronic hepatitis."..
  57. ncbi Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California 94304, USA
    Am J Gastroenterol 104:2206-13. 2009
    ..This study hypothesizes that a significant proportion of such patients may have histological disease...
  58. ncbi Diabetes mellitus increases the risk of mortality following liver transplantation independent of MELD score
    Andrew L Samuelson
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305 5109, USA
    Dig Dis Sci 55:2089-94. 2010
    ..The aim of this study was to compare the mortality of diabetic and non-diabetic patients following liver transplantation...
  59. ncbi Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data
    Jon Erik C Holty
    Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
    Liver Transpl 15:894-906. 2009
    ..Liver Transpl 15:894-906, 2009. (c) 2009 AASLD...
  60. ncbi The A's and B's of vaccine-preventable hepatitis: improving prevention in high-risk adults
    Edward C Oldfield
    Division of Infectious Diseases, Department of Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Rev Gastroenterol Disord 7:1-21. 2007
    ..The use of a combined vaccination, possibly using an accelerated administration schedule, provides convenience and may increase compliance...
  61. ncbi Portal hypertensive hemorrhage from a left gastroepiploic vein caput medusa in an adhesed umbilical hernia
    Daniel Y Sze
    Division of Cardiovascular and Interventional Radiology, Stanford University Medical Center, California 94305 5642, USA
    J Vasc Interv Radiol 16:281-5. 2005
    ..Refractory hemorrhage from this caput medusa was successfully treated by transjugular intrahepatic portosystemic shunt creation and balloon-occluded variceal sclerosis...
  62. ncbi Patient selection criteria for liver transplantation
    A S Yu
    Divsion of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94304-1509, USA
    Minerva Chir 58:635-48. 2003
    ..Other options that are being explored to expand the donor pool include the use of marginal donors, split liver transplants, living donors, and domino transplants, with xenotransplantation still remaining experimental...
  63. ncbi Diagnosis and treatment of chronic hepatitis B: an update
    M Morgan
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Minerva Gastroenterol Dietol 53:25-41. 2007
    ....
  64. ncbi Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes
    Judie Boisvert
    Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Hepatol 38:67-75. 2003
    ..Chemokines and their receptors are important regulators of immunity, particularly in the migration and localization of circulating leukocytes within peripheral tissues...
  65. ncbi Best of the AASLD. Highlights from the 52nd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-13, 2001, Dallas, TX
    Emmet B Keeffe
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA
    Rev Gastroenterol Disord 2:34-40. 2002
  66. ncbi Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection
    Holbrook E Kohrt
    Division of Hematology, Department of Medicine, Stanford University Medical Center, 300 Pasteur Drive, S101, Stanford, CA 94305 5109, USA
    Clin Liver Dis 11:965-91, x. 2007
    ....
  67. ncbi Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma
    Stephen N Wong
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Liver Transpl 13:334-42. 2007
    ..In conclusion, despite more advanced liver disease and a lower rate of transplantation, ITT survival of patients listed for HBV-cirrhosis was comparable to those with HBV-HCC, possibly related to beneficial effects of antiviral therapy...
  68. ncbi Chronic hepatitis C in the human immunodeficiency virus-infected patient: management strategies
    Debika Bhattacharya
    Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Gastroenterol Hepatol 4:288-92. 2006
  69. ncbi Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Gastroenterol Hepatol 2:820-4. 2004
    ..These results need confirmation in larger studies from racially diverse populations, but, if confirmed, these results point to high-risk populations that should be targeted for screening and preventive efforts...
  70. ncbi Hepatitis B virus genotypes in the United States: results of a nationwide study
    Chi-Jen Chu
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109-0362, USA
    Gastroenterology 125:444-51. 2003
    ..HBV genotypes may account for the heterogeneity in disease manifestations among patients with chronic HBV infection...
  71. ncbi Diagnosis and treatment of chronic hepatitis B
    W Park
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304-1509, USA
    Minerva Gastroenterol Dietol 50:289-303. 2004
    ....
  72. ncbi Detection and treatment of coronary artery disease in liver transplant candidates
    B G Keeffe
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304-1509, USA
    Liver Transpl 7:755-61. 2001
    ..Prospective studies regarding optimal screening strategies for the presence of CAD and the indications, timing, and outcomes of interventional therapy in patients with advanced cirrhosis are lacking and much needed...
  73. ncbi Diagnosis and treatment of chronic hepatitis B: 2009 update
    M Morgan
    Division of Gastroenterology and Hepatology Department of Medicine, Stanford University, Medical Center, Stanford, CA, USA
    Minerva Gastroenterol Dietol 55:5-22. 2009
    ....
  74. ncbi Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection
    S Auffermann-Gretzinger
    Divisions of Oncology and of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305-5151, USA
    Blood 97:3171-6. 2001
    ..Blood. 2001;97:3171-3176)..
  75. ncbi Management of chronic liver failure until liver transplantation
    Gaurav Arora
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Room M211, Stanford, CA 94305 5187, USA
    Med Clin North Am 92:839-60, ix. 2008
    ..Once a patient who has chronic liver failure develops hepatic decompensation, liver transplantation is the definitive treatment for those who qualify. Management of chronic liver failure is the focus of this article...
  76. ncbi Current indications and contraindications for liver transplantation
    Aijaz Ahmed
    Division of Gastroenterology and Hepatology, Liver Transplant Program, Stanford University School of Medicine, Stanford, CA 94304, USA
    Clin Liver Dis 11:227-47. 2007
    ..Currently, the Model for End-stage Liver Disease score is used for organ allocation, but it may have future application in patient-selection criteria...
  77. ncbi Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94304-1509, USA
    Hepatology 36:410-7. 2002
    ..56 for African Americans. In conclusion, AFP greater than 200 ng/mL can be used to confirm HCC in patients with HCV-related cirrhosis and a hepatic mass. However, AFP is insensitive for the diagnosis of HCC in African Americans...
  78. ncbi Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine
    Nicole D Simpson
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California 94304, USA
    J Clin Gastroenterol 37:68-71. 2003
    ....
  79. ncbi Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies
    Nam On Ku
    Department of Medicine, Palo Alto Veterans Affairs Medical Center, 3801 Miranda Avenue, 154J, Palo Alto, CA 94304, USA
    Proc Natl Acad Sci U S A 100:6063-8. 2003
    ..03). Therefore, K8K18 are likely susceptibility genes for developing cryptogenic and noncryptogenic forms of liver disease...
  80. ncbi Liver transplantation for alcoholic liver disease: current concepts and length of sobriety
    Joseph K Lim
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Liver Transpl 10:S31-8. 2004
    ..There are no good data to determine if some patients with sobriety fewer than 6 months might benefit from liver transplantation...
  81. ncbi Quality of life and employment after liver transplantation
    D M Bravata
    Department of Medicine, Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, CA, USA
    Liver Transpl 7:S119-23. 2001
    ....
  82. ncbi Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion
    B Y Ha
    Division of GI and Hepatology, Stanford University School of Medicine, Stanford, CA 94304 1509, USA
    Aliment Pharmacol Ther 26:839-46. 2007
    ..Published studies of TACE report a 5-16% risk of serious complications. Compared with TACE, transcatheter arterial chemoinfusion (TACI) may have similar efficacy and fewer side effects...
  83. ncbi Nonalcoholic fatty liver disease
    Andy S Yu
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Liver Transplant Program, Stanford University Medical Center, Stanford, CA, USA
    Rev Gastroenterol Disord 2:11-9. 2002
    ..Treatment is aimed at correcting the risk factors for NAFLD and using potentially hepatoprotective agents. Ursodeoxycholic acid and betaine appear particularly promising in early trials...
  84. ncbi Fulminant hepatic failure secondary to neoplastic infiltration of the liver
    Pankaj Rajvanshi
    Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle, WA 98195-6424, USA
    J Clin Gastroenterol 39:339-43. 2005
    ..Neoplastic involvement of liver should be considered in the differential diagnosis of FHF of unknown etiology. The imaging studies in this setting can be misleading...
  85. ncbi Older age and liver transplantation: a review
    Rajesh N Keswani
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Liver Transpl 10:957-67. 2004
    ....
  86. ncbi Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time?
    Seth D Crockett
    Department of Medicine, Stanford University Medical Center, 750 Welch Road, Stanford, CA 94034, USA
    Clin Liver Dis 10:513-34, viii. 2006
    ..This article reviews the results of recent published and preliminary studies on serum markers, focusing on their comparison with liver biopsy and their clinical utility...
  87. ncbi The epidemiology of hepatitis C virus infection
    Tommy Yen
    Division of General Internal Medicine and Geriatrics, VA San Diego Hepatitis C Clinic, Veteran's Adminstration Medical Center, and University of California, San Diego School of Medicine, San Diego, California, USA
    J Clin Gastroenterol 36:47-53. 2003
    ..We review the literature regarding the incidence and prevalence of HCV infection and the evidence supporting various modes of HCV transmission...
  88. ncbi Management of hepatocellular carcinoma
    Andy S Yu
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA
    Rev Gastroenterol Disord 3:8-24. 2003
    ..Tamoxifen did not improve survival in large clinical trials. Gene therapy is an exciting approach to treating HCC but is still largely confined to preclinical and experimental settings...
  89. ncbi Acute pancreatitis after gastrointestinal endoscopy
    Andrew B Nevins
    Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, California 94304-1509, USA
    J Clin Gastroenterol 34:94-5. 2002
    ....
  90. ncbi Screening for hepatocellular carcinoma
    Mindie H Nguyen
    Division of Gastroenterology and Hepatology, Department ofMedicine, Santford, California 94304 1509, USA
    J Clin Gastroenterol 35:S86-91. 2002
    ..This article will review the current recommendations for HCC screening, the rationale that led to these recommendations, and the challenges of cost-effectiveness research in this area...
  91. ncbi Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C
    Jean Francois Rossignol
    The Romark Institute for Medical Research, Romark Laboratories, LC, Tampa, FL 33607, USA
    Future Microbiol 3:539-45. 2008
    ..Randomized, controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 and patients with chronic hepatitis B are underway, and new second generation thiazolides are being developed...
  92. ncbi Management of antiviral resistance in patients with chronic hepatitis B
    Stephen Locarnini
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia
    Antivir Ther 9:679-93. 2004
    ..Potential strategies to prevent the emergence of resistance and how to manage drug-resistant HBV once it emerges are discussed...
  93. ncbi Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties
    Eithan Galun
    Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital, Jerusalem, Israel
    Hepatology 35:673-9. 2002
    ..In conclusion, these data suggest that HBV-AB(XTL) binds HBV particles and reduces serum viral titers and HBsAg levels. HBV-AB(XTL) could be combined with other monotherapies that are currently used to treat HBV carriers...
  94. ncbi Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy
    David R Berk
    Division of Dermatology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Gastroenterol Hepatol 5:142-51. 2007
    ..This review summarizes available data on dermatologic conditions associated with chronic HCV and their response to IFN therapy...
  95. ncbi Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin
    Vijayan Balan
    Division of Transplantation Medicine, Mayo Clinic Hospital, 5777 E. Mayo Boulevard, Phoenix, AZ 85054, USA
    Am J Gastroenterol 100:299-307. 2005
    ..CONCLUSIONS: HCV-infected patients receiving PEG-IFN/RBV therapy have reductions in Hb, platelets, and WBCs, possibly due to bone marrow suppression. They also have diminished endogenous sEPO production for their degree of anemia...
  96. ncbi Impact of age older than 60 years in living donor liver transplantation
    Kaori Kuramitsu
    Department of Transplant Surgery, Kyoto University Hospital, corrected Kyoto, Japan
    Transplantation 84:166-72. 2007
    ..The impact of donor age, analysis of preoperative risk factors for older LDLT recipients, and comparison of the complication rate between older and younger recipients were analyzed...
  97. ncbi Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...
  98. ncbi Hepatitis B: explosion of new knowledge
    Emmet B Keeffe
    Gastroenterology 133:1718-21. 2007
  99. ncbi Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels
    Philip S Y Tsang
    University of Toronto, Toronto, Canada
    Clin Gastroenterol Hepatol 6:569-74. 2008
    ..Serum ALT remains the most accessible test available to clinicians for monitoring chronic hepatitis B virus infection, but appropriate action when ALT levels are only mildly elevated is ambiguous in standard guidelines...
  100. ncbi Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Liver Transpl 8:433-9. 2002
    ....
  101. ncbi Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry
    Kris V Kowdley
    University of Washington, Seattle, 98195, USA
    Gastroenterology 129:494-503. 2005
    ..We examined the effect of HFE mutations on posttransplantation survival in patients with hepatic iron overload...